Company news
Correvio Pharma Corp news in 2013
Correvio Pharma Corp's news releases, calls and decks from 2013, newest first.
Europace Publishes Data Supporting Use Of BRINAVESS(TM) (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation
November 21, 2013
Cardiome To Acquire Correvio LLC
November 18, 2013
Cardiome Reports Third Quarter 2013 Financial Results
November 6, 2013
Cardiome Announces Presentation at Medical Conference and Provides Update on Journal Publications for Vernakalant
October 28, 2013
Cardiome To Hold Third Quarter 2013 Financial Results Conference Call On November 6
October 24, 2013
Cardiome Enters Commercialization Agreement With Algorithm S.A.L. For BRINAVESS(TM) In Middle East And North Africa
October 21, 2013
Cardiome Announces Commercialization Agreement With Biospifar S.A. For BRINAVESS(TM) In Colombia
October 9, 2013
Cardiome Announces Publication of Positive Data from an Observational, Retrospective Study of BRINAVESS
October 7, 2013
Cardiome Receives Approval For BRINAVESS(TM) In South Africa
September 30, 2013
Cardiome Receives Approval For BRINAVESS(TM) In Turkey
September 25, 2013
Cardiome Announces Commercialization Partnership with LifePharma (Z.A.M) Ltd. for BRINAVESS(TM) in Cyprus
September 24, 2013
Cardiome Announces Publication Of Positive Data From A Study Comparing Vernakalant IV Versus Propafenone And Flecainide
September 23, 2013
Cardiome Announces Commercialization Agreement With Tzamal Medical Group For Brinavess(TM) In Israel
September 17, 2013
Cardiome Completes Transfer Of Commercialization Responsibility For Brinavess(TM) In The EU
September 16, 2013
Cardiome Announces Its Presence At The ESC Congress 2013 In Amsterdam
August 29, 2013
Cardiome Reports Second Quarter 2013 Financial Results
August 2, 2013
Cardiome to Hold Second Quarter 2013 Financial Results Conference Call on August 2
July 19, 2013
Cardiome Announces Commercialization Partnership For BRINAVESS(TM) In Select European Markets
July 3, 2013
Cardiome Announces the Transfer of European Marketing Authorization from Merck
June 27, 2013
Cardiome Adopts Advance Notice Policy
May 28, 2013
Cardiome Reports First Quarter Results
May 13, 2013
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
May 10, 2013
Cardiome to Hold First Quarter 2013 Financial Results Conference Call on May 13
May 9, 2013
Cardiome Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings from Merck
May 2, 2013